Next Article in Journal
The Saccharomyces boulardii CNCM I-745 Strain Shows Protective Effects against the B. anthracis LT Toxin
Next Article in Special Issue
Current Status and Future Directions of Botulinum Neurotoxins for Targeting Pain Processing
Previous Article in Journal
Editorial on the Special Issue “Harmful Algal Blooms (HABs) and Public Health: Progress and Current Challenges”
Previous Article in Special Issue
The Inhibitory Effect of Botulinum Toxin Type A on Rat Pyloric Smooth Muscle Contractile Response to Substance P In Vitro
Open AccessArticle

Acupoint Injection of Onabotulinumtoxin A for Migraines

1
Department of Neuroscience, Anatomy, Histology and Embryology, Key Laboratory of Preclinical Study for New Drugs of Gansu Province, School of Basic Medical Sciences, Lanzhou University, 199 Donggang Xi Road, Lanzhou 730000, China
2
Department of Anatomy, Gansu University of Traditional Chinese Medicine, Lanzhou 730000, China
3
Department of Human Anatomy, School of Medicine, Hunan Normal University, 371 Tongzipo Road, Changsha 410013, China
4
Department of Neurology and Pain Treatment, Gansu Province People Hospital, Lanzhou 730000, China
*
Author to whom correspondence should be addressed.
Academic Editor: Bahman Jabbari
Toxins 2015, 7(11), 4442-4454; https://doi.org/10.3390/toxins7114442
Received: 25 July 2015 / Revised: 20 October 2015 / Accepted: 20 October 2015 / Published: 30 October 2015
(This article belongs to the Collection Botulinum Toxins on Human Pain)
Onabotulinumtoxin A (BoNTA) has been reported to be effective in the therapy for migraines. Acupuncture has been used worldwide for the treatment of migraine attacks. Injection of a small amount of drug at acupuncture points is an innovation as compared to traditional acupuncture. The purpose of this study was to evaluate and compare the effectiveness of fixed (muscle)-site and acupoint-site injections of BoNTA for migraine therapy in a randomized, double-blinded, placebo-controlled clinical trial extending over four months. Subjects with both episodic and chronic migraines respectively received a placebo (n = 19) or BoNTA (2.5 U each site, 25 U per subject) injection at fixed-sites (n = 41) including occipitofrontalis, corrugator supercilii, temporalis and trapeziue, or at acupoint-sites (n = 42) including Yintang (EX-HN3), Taiyang (EX-HN5), Baihui (GV20), Shuaigu (GB8), Fengchi (GB20) and Tianzhu (BL10). The variations between baseline and BoNTA post-injection for four months were calculated monthly as outcome measures. BoNTA injections at fixed-sites and acupoint-sites significantly reduced the migraine attack frequency, intensity, duration and associated symptoms for four months compared with placebo (p < 0.01). The efficacy of BoNTA for migraines in the acupoint-site group (93% improvement) was more significant than that in the fixed-site group (85% improvement) (p < 0.01). BoNTA administration for migraines is effective, and at acupoint-sites shows more efficacy than at fixed-sites. Further blinded studies are necessary to establish the efficacy of a low dose toxin (25 U) introduced with this methodology in chronic and episodic migraines. View Full-Text
Keywords: botulinum toxin type A; migraine; fixed-sites injection; acupoint-sites injection; randomized and placebo-controlled trial botulinum toxin type A; migraine; fixed-sites injection; acupoint-sites injection; randomized and placebo-controlled trial
Show Figures

Figure 1

MDPI and ACS Style

Hou, M.; Xie, J.-F.; Kong, X.-P.; Zhang, Y.; Shao, Y.-F.; Wang, C.; Ren, W.-T.; Cui, G.-F.; Xin, L.; Hou, Y.-P. Acupoint Injection of Onabotulinumtoxin A for Migraines. Toxins 2015, 7, 4442-4454.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Search more from Scilit
 
Search
Back to TopTop